Patents Examined by Allison M Fox
-
Patent number: 11965190Abstract: Provided herein are a vector, a genetically modified bacterium including the vector, methods of making the bacterium, methods of using the bacterium, and kits including the bacterium. The vector includes a coding region encoding at least one antimicrobial peptide, and the antimicrobial peptide includes at least one lysin.Type: GrantFiled: September 7, 2018Date of Patent: April 23, 2024Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Yiannis John Kaznessis, Seth Ritter, Benjamin Hackel
-
Patent number: 11963990Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.Type: GrantFiled: May 24, 2023Date of Patent: April 23, 2024Assignee: KaliVir Immunotherapeutics, Inc.Inventors: Stephen Howard Thorne, Mingrui Zhang
-
Patent number: 11965180Abstract: Provided is a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. A human cancer tissue was repeatedly grown in a NOG mouse, separated cancer cells from the grown cancer tissue, and tested and compared various cancer cell culture processes. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process.Type: GrantFiled: August 14, 2020Date of Patent: April 23, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Patent number: 11957718Abstract: The invention provides compositions comprising multipotent progenitor cells isolated from tonsillar tissue and differentiated cells derived therefrom and methods for using the cells for the treatment of diseases or disorders.Type: GrantFiled: December 22, 2017Date of Patent: April 16, 2024Assignee: University of Maryland, BaltimoreInventors: Michal Zalzman, Rodney Taylor
-
Patent number: 11957720Abstract: The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.Type: GrantFiled: April 27, 2022Date of Patent: April 16, 2024Assignee: Societe des Produits Nestle S.A.Inventors: Peter McLean, Gabriela Bergonzelli Degonda, Stephen Michael Collins, Premysl Bercik, Elena Verdu de Bercik
-
Patent number: 11959120Abstract: Provided herein are methods of producing oils with reduced saturated fatty acids. The methods include culturing oil-producing microorganisms in a fermentation medium in the presence of one or more antifoaming agents under a controlled carbon consumption rate, wherein the culturing produces oils comprising fatty acids and wherein less than 35% of the fatty acids in the oil are saturated fatty acids.Type: GrantFiled: October 28, 2020Date of Patent: April 16, 2024Assignee: MARA Renewables CorporationInventors: Zhiyong Sun, Alan Sothern, Kevin Berryman, Mercia Valentine, Michael Milway, Laura Purdue, Roberto E. Armenta
-
Patent number: 11951138Abstract: A method of mimicking a phenotype of a first ruminating animal in a second ruminating animal is disclosed. The method comprises administering to the second ruminating animal a microbial composition comprising a plurality of microbes having a signature which is statistically significantly similar to the microbial signature of a rumen microbiome of the first ruminating animal, wherein the first and the second ruminating animal are of identical species, thereby mimicking the phenotype of the first ruminating animal in the second ruminating animal.Type: GrantFiled: March 13, 2014Date of Patent: April 9, 2024Assignee: The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center)Inventors: Itzhak Mizrahi, Elie Jami
-
Patent number: 11952605Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.Type: GrantFiled: February 22, 2023Date of Patent: April 9, 2024Assignee: Amgen Inc.Inventors: Jian Wu, Sean Davern, Simina Crina Petrovan, Michael Charles Brandenstein, Katherine Rose Lindahl, Shawn Erik Lillie
-
Patent number: 11951131Abstract: Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.Type: GrantFiled: June 26, 2019Date of Patent: April 9, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: James N. Kochenderfer, Steven A. Feldman
-
Patent number: 11944647Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: GrantFiled: June 22, 2022Date of Patent: April 2, 2024Assignee: Juno Therapeutics, Inc.Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
-
Patent number: 11944718Abstract: The disclosure herein relates to isolated and purified mammalian fetal allografts and kits and compositions containing these. Also disclosed are methods of preparing isolated and purified mammalian fetal allografts; methods of contacting a wound of a subject with these, and methods of treating a disease or condition with these.Type: GrantFiled: December 16, 2022Date of Patent: April 2, 2024Assignee: Healthtech Solutions, Inc.Inventors: Bradley Robinson, Douglas Ivins Schmid, Thayne Sherman Ekness
-
Patent number: 11946070Abstract: The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.Type: GrantFiled: July 15, 2020Date of Patent: April 2, 2024Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Duk Lyul Na, Jong Wook Chang, Hyo Jin Son
-
Patent number: 11939593Abstract: Compositions and methods for improving embryo development, treating idiopathic male factor infertility, and enabling infertile/sub-fertile/sterile men to father their own genetic offspring are provided. Typically, the methods include administering into a male or female gamete or fertilized embryo an effective amount of a compound that increases bioavailability of a TET protein to improve development of an embryo resulting from fertilization of the female gamete by a male gamete. The compound can be administered into the gamete or embryo before, during, or after fertilization. The compound can be administered by an injection such as intracytoplasmic injection. The compound and the male gamete can be administered in combination by intracytoplasmic sperm injection. Methods of making male gametes, and methods of modifying the genome of a male gamete or embryo using an effective amount of a gene editing composition to correct a gene mutation or anomaly in the genome thereof are also provided.Type: GrantFiled: August 1, 2019Date of Patent: March 26, 2024Assignees: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., EMORY UNIVERSITYInventors: Charles A. Easley, IV, Anthony W. S. Chan
-
Patent number: 11931401Abstract: In the present invention, it was confirmed that the modified protein in which the 356th serine of Runx3 is substituted with alanine has an increased activity of maintaining the complex with Brd2 by more than 10 times compared to the wild-type Runx3, and the apoptosis effect is improved in various cancer cell lines compared to the wild-type Runx3. Therefore, the modified protein in which the 356th serine of Runx3 is substituted with an amino acid that cannot be phosphorylated by a kinase of the present invention, the polynucleotide coding thereof, the vector carrying the polynucleotide, or the virus or cell transformed with the vector can be used as a therapeutic agent for various cancers.Type: GrantFiled: April 23, 2021Date of Patent: March 19, 2024Assignee: GeneCraft Inc.Inventors: Suk Chul Bae, Jung Won Lee, You Soub Lee
-
Patent number: 11932846Abstract: A system for expressing a chloramphenicol split protein is disclosed. Uses thereof are also disclosed.Type: GrantFiled: August 8, 2018Date of Patent: March 19, 2024Assignee: Technology Innovation Momentum Fund (Israel) Limited PartnershipInventor: Gali Prag
-
Patent number: 11930824Abstract: The present algae extracts are used for biocontrol of insects. Specifically, the present extracts are obtained from Cystoseria muricatum using a polysolvent system. Once obtained, the extracts can be applied to plants to repel insects and/or to facilitate fertilization of the plants.Type: GrantFiled: March 22, 2023Date of Patent: March 19, 2024Assignee: KING FAISAL UNIVERSITYInventor: Nermin Adel El Semary
-
Patent number: 11932876Abstract: The present disclosure provides methods for forming stable three-dimensional vascular structures, such as blood vessels and uses thereof. More specifically, the present disclosure provides methods for culturing differentiated endothelial cells that include an exogenous nucleic acid encoding ETV2 transcription factor on a matrix under conditions that express exogenous ETV2 protein in the endothelial cell to form stable three-dimensional artificial blood vessels without the use of a scaffold, pericytes or perfusion. The present disclosure also provides stable three-dimensional blood vessels that are capable of autonomously forming a functional three-dimensional vascular network, and uses thereof.Type: GrantFiled: February 2, 2018Date of Patent: March 19, 2024Assignee: CORNELL UNIVERSITYInventors: Shahin Rafii, Brisa Palikuqi
-
Patent number: 11931458Abstract: The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.Type: GrantFiled: January 10, 2022Date of Patent: March 19, 2024Inventors: Babak Ghalili, Keyon Janani, Peter Scherp, John Borja
-
Patent number: 11925726Abstract: The present disclosure is related to a perfusable-type bio-dual proximal tubule cell construct and a producing method thereof capable of applying an in vitro artificial organ model configured to include a first bioink comprising a decellularized substance derived from a mammalian kidney tissue and human umbilical vascular endothelial cells (HUVECs) and a second bioink comprising the decellularized substance and renal proximal tubular epithelial cells (RPTECs), wherein the first bioink and the second bioink are coaxial and printed in tubular constructs having different inner diameters. According to the present disclosure, it is possible to use the renal proximal tubule-on-a-chip as a bioreactor capable of observing a biological drug reaction similar to a real drug by perfusing various drugs to the renal proximal tubule-on-a-chip.Type: GrantFiled: December 18, 2020Date of Patent: March 12, 2024Assignees: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION, THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY—ACADEMIC COOPERATION FOUNDATIONInventors: Dong-Woo Cho, Wonil Han, Narendra K. Singh, Yong Kyun Kim, Sun Ah Nam
-
Patent number: 11925532Abstract: A vented wound dressing barrier includes one or more membrane layers with a plurality of vents. The vents are cut along a perimeter of the vents through the one or more membrane layers. Each vent having a connection portion uncut relative to the one or more membrane layers thereby forming a hinge configured to allow the vents to open for drainage when exposed to fluid underlying the vented wound dressing barrier. The plurality of vents is each cut along the perimeter without removal of any of the membrane layer. The one or more membrane layers with the plurality of vents has a surface for covering a wound, the surface area in the absence of a fluid pressing on the vents having no openings or voids which reduce the surface area of a vented wound dressing barrier area covering a wound.Type: GrantFiled: December 10, 2021Date of Patent: March 12, 2024Assignee: Vivex Biologics Group, Inc.Inventors: Timothy Ganey, Shabnam Namin, Hanna Kaliada, Santiago Osorio